ArticleVirulence2021
Verapamil inhibits efflux pumps in
Article in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07505446 (Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Patients in South Egypt Cancer Institute), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Patients in South Egypt Cancer Institute
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- The Potential Role of Verapamil Against Fluconazole-Induced Torsade de Pointes: A Critical Review.Health science reports · 2026Article
- Identification of efflux inhibitors through a drug repurposing strategy inFrontiers in cellular and infection microbiology · 2026Article
- In Vitro Evaluation of 5-Fluorouridine as an Adjuvant to Antifungal Drugs and Molecular Insights into Resistance to This Compound inInternational journal of molecular sciences · 2025Article
- Review
- Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence.AMB Express · 2025Article
- Article
- The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model.BMC microbiology · 2024Article
- Quantification methods ofMicrobial cell (Graz, Austria) · 2024Article
- Structural and functional investigation of ABC transporter STE6-2p fromProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinicalSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi-Latest Findings.Antibiotics (Basel, Switzerland) · 2021Review
- Antimicrobial Activity of Curcumin in Nanoformulations: A Comprehensive Review.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of resistance requires alternative methods to treat
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.